Senotherapeutics – driving lifespan and healthspan

Latest articles

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

X marks the spot for meaningful information on aging and cognition

Understanding chromosomal differences between men and women could be the X Factor when it comes to tackling cognitive decline. A new paper published in Jama...

Most read

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Editor's picks

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

Click the globe for translations.

Taking senescence seriously: our video briefing dives into the biology of aging, the different areas of senotherapeutic research and the drivers for a market that could be worth $127 billion.

Cellular senescence is one of the nine hallmarks of aging, and research points to a direct, actionable link between senescent cells and longevity. Our new market intelligence report provides a detailed analysis of the emerging biotech field focused on targeting cellular senescence.

Longevity.Technology: Today we launch our senotherapeutics briefing video. As well as explaining what senescence is, we unpick the different senotherapeutic therapies and assess their challenges and opportunities. We also analyse the market drivers (socioeconomic, economic, political), overview the regulatory environment and examine the investment potential, especially in light of the focus on geroprotection in the post-COVID world.

The aging population is increasing, and, therefore, so is concern. The so-called “Silver Tsunami” threatens to lay waste to healthcare provision, economies and associated infrastructure. Senotherapeutics could be the lifebelt we desperately need to tackle the age-driven incidence rate of chronic disease, and to support additional years of healthy life.

Ovarian Longevity webinar

Age could be just how you are, not a limitation or a usefulness expiry date.

Dive into the world of senolytics, senomodulators, senoblockers and senescence-associated immunomodulators as Editor-in-Chief Phil Newman and Scientific Writer Girish Harinath explain the longevity potential of tackling senescence; Longevity.Technology estimates that the combined market value of diseases that could be addressed by senotherapeutics, including macular degeneration, chronic kidney disease, type 2 diabetes and neurodegenerative disease, amounts to more than $127 billion.

Ovarian Longevity webinar

Access the report as a download or subscription HERE and check out our senotherapeutic company profiles HERE.

Image courtesy of  Roberto Nickson / Unsplash
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...

Related articles

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Fauna closes $9 million to expand drug discovery platform

Leveraging animal genomics to improve human health, Fauna Bio set to expand its comparative genomics platform for novel target drug discovery. Silicon Valley biotech startup...

Smartphone-sized bioartificial kidney prototype passes key test

The Kidney Project successfully tests a prototype bioartificial kidney and wins KidneyX’s $650,000 Artificial Kidney Prize. The Kidney Project’s implantable bioartificial kidney, one that promises...

Shifting gear: startup aims to de-risk rejuvenation therapy

Shift Bioscience raising funding to develop safe cellular reprogramming therapies for rejuvenation. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the...

Senolytic cocktail reduces aging-associated disc degeneration

Senolytic drug therapies that target aging cells early pave the way to easing back pain. New findings, reported in Nature Communications, show how a novel...
Nutriop